Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 15/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4168906 | 0.98 | SIGMAR1 (0.76) | SIGMAR1CYP1A2CYP2D6TMEM97TDP1 | |
| SCHEMBL4169180 | 0.85 | SIGMAR1 (0.61) | SIGMAR1CYP1A2CYP2D6TMEM97 | |
| SCHEMBL8306739 | 0.83 | CYP1A2 (0.67) | SIGMAR1CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL16026648 | 0.83 | HRH3 (0.84) | SIGMAR1CYP1A2TDP1L3MBTL1HRH3 | |
| SCHEMBL467155 | 0.82 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP2D6TMEM97CYP3A4 | |
| SCHEMBL29472420 | 0.82 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP2D6TMEM97CYP3A4 | |
| Hydrochloric Acid SCHEMBL30570469 | 0.81 | SIGMAR1 (0.97) | SIGMAR1CYP1A2CYP2D6TMEM97CYP3A4 | |
| Hydrochloric Acid SCHEMBL2727622 | 0.81 | SIGMAR1 (0.97) | SIGMAR1CYP1A2CYP2D6TMEM97CYP3A4 | |
| SCHEMBL7528803 | 0.81 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP2D6TMEM97HTR1A | |
| SCHEMBL5804316 | 0.80 | SIGMAR1 (0.93) | SIGMAR1CYP1A2CYP2D6TMEM97CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | claimed |
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
| EP-1981849-A1 | HETEROCYCLIC COMPOUNDS | LEK Pharmaceuticals D.D. (SI) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007073935-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007073935-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | CYP51A1, DHCR7, LSS | SIGMAR1 1948/4885CYP1A2 110/4885CYP2D6 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.